{"id":"https://openalex.org/W4415900331","doi":"https://doi.org/10.1136/jitc-2025-sitc2025.1190","title":"1190 OSE-cytomask\u00ae, a novel CIS-demasking cytokine technology to increase therapeutic index of immunocytokine","display_name":"1190 OSE-cytomask\u00ae, a novel CIS-demasking cytokine technology to increase therapeutic index of immunocytokine","publication_year":2025,"publication_date":"2025-11-01","ids":{"openalex":"https://openalex.org/W4415900331","doi":"https://doi.org/10.1136/jitc-2025-sitc2025.1190"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2025-sitc2025.1190","doi":"https://doi.org/10.1136/jitc-2025-sitc2025.1190","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2025-sitc2025.1190","pdf_url":"https://jitc.bmj.com/content/13/Suppl_2/A1356.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/13/Suppl_2/A1356.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052078960","display_name":"Margaux Seit\u00e9","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Margaux Seite","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, Loire-Atlantique, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, Loire-Atlantique, France","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109591004","display_name":"Caroline Mary","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Caroline Mary","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, Loire-Atlantique, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, Loire-Atlantique, France","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032120204","display_name":"Virginie Th\u00e9penier","orcid":"https://orcid.org/0000-0003-3675-9281","observed_orcids":["https://orcid.org/0000-0003-3675-9281"]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Virginie Thepenier","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, Loire-Atlantique, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, Loire-Atlantique, France","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046464434","display_name":"C\u00e9cile Batty","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Cecile Batty","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, Loire-Atlantique, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, Loire-Atlantique, France","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087659024","display_name":"G\u00e9raldine Teppaz","orcid":"https://orcid.org/0000-0002-5835-2493","observed_orcids":["https://orcid.org/0000-0002-5835-2493"]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Geraldine Teppaz","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, Loire-Atlantique, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, Loire-Atlantique, France","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051999530","display_name":"Virginie Aillerie","orcid":"https://orcid.org/0000-0003-2765-2626","observed_orcids":["https://orcid.org/0000-0003-2765-2626"]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Virginie Aillerie","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, Loire-Atlantique, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, Loire-Atlantique, France","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029438699","display_name":"Justine Durand","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Justine Durand","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, Loire-Atlantique, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, Loire-Atlantique, France","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075730887","display_name":"K\u00e9vin Biteau","orcid":"https://orcid.org/0009-0004-4391-2701","observed_orcids":["https://orcid.org/0009-0004-4391-2701"]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Kevin Biteau","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, Loire-Atlantique, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, Loire-Atlantique, France","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017896084","display_name":"Amandine Georges","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Amandine Georges","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, Loire-Atlantique, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, Loire-Atlantique, France","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048543389","display_name":"Nicolas Poirier","orcid":"https://orcid.org/0000-0003-2335-9385","observed_orcids":["https://orcid.org/0000-0003-2335-9385"]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Nicolas Poirier","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, Loire-Atlantique, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, Loire-Atlantique, France","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5023411196","display_name":"Aurore Morello","orcid":"https://orcid.org/0000-0003-3202-3779","observed_orcids":["https://orcid.org/0000-0003-3202-3779"]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Aurore Morello","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, Loire-Atlantique, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, Loire-Atlantique, France","institution_ids":["https://openalex.org/I4210101439"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210101439"],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A1356","last_page":"A1356"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.4884999990463257,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.4884999990463257,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.4203999936580658,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.020800000056624413,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immunocytokines","display_name":"immunocytokines","score":0.9649999737739563},{"id":"https://openalex.org/keywords/non-cleavable-linkers","display_name":"non-cleavable linkers","score":0.8090000152587891},{"id":"https://openalex.org/keywords/anti-pd-1-antibody","display_name":"anti-PD-1","score":0.8180000185966492},{"id":"https://openalex.org/keywords/interleukin-2","display_name":"interleukin-2","score":0.7059999704360962},{"id":"https://openalex.org/keywords/il-15","display_name":"IL-15","score":0.9879999756813049},{"id":"https://openalex.org/keywords/pd-1-t-cells","display_name":"PD-1+ T cells","score":0.6710000038146973},{"id":"https://openalex.org/keywords/therapeutic-index","display_name":"therapeutic index","score":0.8320000171661377},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.4950000047683716},{"id":"https://openalex.org/keywords/mc38-tumor-model","display_name":"MC38 tumor","score":0.6309999823570251}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6705999970436096},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.5209000110626221},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3950999975204468},{"id":"https://openalex.org/C2777382242","wikidata":"https://www.wikidata.org/wiki/Q6017816","display_name":"Index (typography)","level":2,"score":0.3537999987602234},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.3465999960899353},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3075000047683716},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.26179999113082886},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.24410000443458557},{"id":"https://openalex.org/C19831878","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Therapeutic index","level":3,"score":0.23829999566078186},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.23729999363422394}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/jitc-2025-sitc2025.1190","doi":"https://doi.org/10.1136/jitc-2025-sitc2025.1190","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2025-sitc2025.1190","pdf_url":"https://jitc.bmj.com/content/13/Suppl_2/A1356.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2025-sitc2025.1190","doi":"https://doi.org/10.1136/jitc-2025-sitc2025.1190","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2025-sitc2025.1190","pdf_url":"https://jitc.bmj.com/content/13/Suppl_2/A1356.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4415900331.pdf","grobid_xml":"https://content.openalex.org/works/W4415900331.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4409627253","https://openalex.org/W4393084633","https://openalex.org/W4388048118","https://openalex.org/W7163068047","https://openalex.org/W4404064415","https://openalex.org/W4412779897","https://openalex.org/W4388080691","https://openalex.org/W4362524684","https://openalex.org/W4392508310","https://openalex.org/W3177619793"],"abstract_inverted_index":{"Background":[0],"Immunocytokines":[1],"are":[2],"promising":[3,385],"therapeutic":[4,115,227,230,257],"approaches":[5],"to":[6,44,50,97,112,125,143,182,240,295,361],"enhance":[7],"T-cell":[8],"response":[9],"by":[10,80,187],"delivering":[11],"interleukins":[12,20],"directly":[13],"into":[14],"the":[15,45,62,94,107,144,180,193,210,246,305,315,388],"tumor.":[16],"The":[17],"fusion":[18],"of":[19,36,65,93,119,165,179,192,197,209,277,314,348,391],"with":[21,148,229,250,261,352,393],"anti-PD-1":[22],"antibodies":[23,355],"has":[24],"shown":[25],"some":[26],"efficacy":[27,215,276],"in":[28,138,195,216,244,282],"preferentially":[29],"cis-activating":[30],"PD1+":[31,166],"T-cells.":[32],"However,":[33],"off-target":[34],"activation":[35,105,164,313],"PD1-negative":[37],"cells":[38,160,168,302],"remains":[39],"a":[40,82,126,225,255,262,334,384],"significant":[41],"challenge":[42],"due":[43],"high":[46],"receptor/cytokine":[47],"affinity,":[48],"leading":[49],"unwanted":[51],"systemic":[52],"effects,":[53],"toxicity":[54,208],"and":[55,84,123,130,137,312,337,356,364,376,396],"low":[56],"tumor":[57],"biodistribution,":[58],"which":[59],"ultimately":[60],"limits":[61],"clinical":[63,389],"potential":[64],"many":[66],"immunocytokines.":[67],"To":[68],"overcome":[69],"these":[70],"limitations,":[71],"we":[72],"developed":[73],"OSE-Cytomask\u00ae":[74,151,204,220,288,325,381],"platform":[75,101,382],"based":[76],"on":[77,106,158,269,298,317,329],"linker":[78,86,152,176,194,253,289,323,350],"technology":[79,153,205,290,351],"designing":[81],"universal":[83],"non-cleavable":[85],"that":[87],"allows":[88],"CIS-cytokine":[89],"demasking":[90],"upon":[91],"binding":[92],"fused":[95,124],"antibody":[96,129],"its":[98,183],"target.":[99],"This":[100],"enables":[102],"precise":[103],"cytokine":[104,156,181,297,316,374],"right":[108],"T":[109,167,173],"cell":[110],"population":[111],"improve":[113],"immunocytokine":[114,146,211,223,392],"index.Methods":[116],"A":[117],"series":[118],"linkers":[120],"were":[121],"screened":[122],"high-affinity":[127],"anti-PD1":[128],"multiple":[131,357],"cytokines":[132,358],"(IL-2/-15/-10/-18...).":[133],"I":[134],"n":[135],"vitro":[136],"vivo":[139],"activity":[140,157,375],"was":[141,280],"compared":[142],"conventional":[145,252],"constructed":[147,249],"(G4S)3":[149,251],"linker.Results":[150],"strongly":[154,206],"decreases":[155],"PD1neg":[159],"while":[161,212,308],"maintaining":[162,213],"strong":[163],"using":[169],"transduced":[170],"and/or":[171],"primary":[172],"cells.":[174,320],"OSE\u00aeCytomask":[175,349],"decreased":[177],"affinity":[178],"receptor":[184],"as":[185],"measured":[186],"Octet,":[188],"confirming":[189],"masking":[190],"properties":[191,347],"absence":[196],"PD-1":[198,284],"targeting.":[199],"Importantly,":[200],"Anti-PD1/IL-15":[201],"or":[202],"IL-2":[203],"reduced":[207],"anti-tumor":[214],"MC38":[217],"ectopic":[218],"model.":[219],"Anti":[221,283],"PD-1/IL2v":[222],"demonstrated":[224],"large":[226],"window":[228],"index":[231,258],"calculated":[232],"at":[233,259,265],"52-fold":[234],"(therapeutic":[235],"dose":[236,264],"from":[237],"0.6mg/kg":[238],"up":[239],"25-30mg/kg":[241],"(3":[242,267],"doses)":[243],"contrast":[245],"same":[247],"molecule":[248],"had":[254],"narrow":[256],"2-fold":[260],"toxic":[263],"2mg/kg":[266],"doses":[268],"Day":[270],"10/12/14":[271],"post-tumor":[272],"inoculation).":[273],"High":[274],"antitumor":[275],"OSE-Cytomask":[278],"IL-2v":[279],"confirmed":[281],"resistant":[285],"PanC02":[286],"models.Conclusions":[287],"illustrates":[291],"specific":[292],"intrinsic":[293],"property":[294],"mask":[296],"na\u00efve":[299],"peripheral":[300],"immune":[301,379],"not":[303,327],"expressing":[304,319],"Antibody":[306],"target":[307],"allowing":[309],"selective":[310],"CIS-demasking":[311],"PD1":[318],"Unlike":[321],"protease-cleavable":[322],"technologies,":[324],"does":[326],"rely":[328],"enzymatic":[330],"activity,":[331],"making":[332],"it":[333],"more":[335,394],"stable":[336],"adaptable":[338],"solution":[339],"across":[340],"different":[341],"TME":[342],"conditions.":[343],"We":[344],"have":[345],"validated":[346],"various":[353],"targeting":[354],"(8":[359],"tested":[360],"date,":[362],"wild-type":[363],"mutant":[365],"sequence)":[366],"including":[367],"IL-15,":[368],"IL-2,":[369],"IL-10":[370],"By":[371],"reducing":[372],"off-tumor":[373],"selectively":[377],"activating":[378],"cells,":[380],"offers":[383],"strategy":[386],"for":[387],"development":[390],"effective":[395],"safer":[397],"properties.":[398]},"counts_by_year":[],"updated_date":"2026-11-13T13:42:25.865203","created_date":"2025-11-05T00:00:00"}